Like TAMs, tumor-associated DCs are heterogeneous, consisting predominantly of myeloid DCs (mDCs) that mediate the adaptive anti-tumor response via activation of CD8+ T-cells and secretion of IL-12, IL-6, and TNF-alpha [46], and plasmacytoid DCs (pDCs) that mediate both adaptive and innate immune responses through antigen presentation and IFNα secretion [47]. The gene discussed is IL6; the disease is neoplasm.